Patients with glaucoma who visited Saitama Medical University and underwent OCTA and mfERG examinations on the same day between February 1, 2020, and April 22, 2021, were included in the study. Glaucoma was diagnosed using the established criteria,
14 which require the presence of at least one of the following: glaucomatous optic neuropathy, repeatable abnormal standard automated perimetry results, abnormal glaucoma hemifield test results, or pattern standard deviation values outside the normal limits. Patients and eyes were excluded if any of the following were present: a history of intraocular surgery (except for cataract or glaucoma surgery), non-glaucomatous optic neuropathy, vascular or nonvascular retinopathy, or another ocular or systemic disease known to impair VF. All participants underwent comprehensive ophthalmic examinations, including assessment of best-corrected visual acuity (Landolt chart), slit-lamp biomicroscopy, measurement of intraocular pressure (Goldmann applanation tonometry), fundus photography (CX-1; Canon, Inc., Tokyo, Japan), measurement of axial length and central corneal thickness (Optical Biometer OA-2000; Tomey Corp., Nagoya, Japan), and standard automated perimetry (Humphrey 24-2 Swedish Interactive Thresholding Algorithm; Carl Zeiss Meditec, Jena, Germany). In addition, all subjects underwent swept-source OCTA (SS-OCTA; PLEX Elite 9000, version 1.6.0.21130; Carl Zeiss Meditec) and spectral-domain OCT (SPECTRALIS HRA 2, Heidelberg Engineering, Heidelberg, Germany) to examine the thicknesses of the macular ganglion cell complex (mGCC) and the macular inner nuclear layer-outer plexiform layer (mINOPL). Self-reported medical histories were extracted from the medical records, including the presence or absence of hypertension, diabetes, and hyperlipidemia.